Pharmacokinetics and pharmacodynamics of ximelagatran
Review published in Seminars in vascular medicine (2005)
Abstract
Oral anticoagulant therapy with vitamin K antagonists (VKAs) such as warfarin has proven benefits in the treatment and prevention of thromboembolic disorders but has important limitations that result in substantial underuse. In particular, the VKAs have variable and unpredictable pharmacokinetics and pharmacodynamics and a narrow separation between antithrombotic and hemorrhagic effects that necessitates careful dose adjustment based on frequent coagulation monitoring. In contrast, the oral direct thrombin inhibitor ximelagatran has a predictable and reproducible pharmacokinetic/pharmacodynamic profile that allows treatment using fixed-dose regimens without coagulation monitoring. The bioavailability of melagatran, the active form of ximelagatran, after oral administration of ximelagatran is approximately 20% with low inter- and intra-individual variability. Peak plasma melagatran concentrations are reached approximately 2 hours after oral dosing of ximelagatran to healthy volunteers, and melagatran is eliminated with a half-life of approximately 3 hours with clearance predominantly by renal excretion. Hence, a higher melagatran exposure is seen in patients with renal failure; ximelagatran is currently not recommended for patients with severe renal impairment (creatinine clearance of <30 mL/min) as these patients were not included in the clinical trial program. Exposure to melagatran increases linearly with the ximelagatran dose. The pharmacokinetic/pharmacodynamic profile is consistent across a broad range of different patient populations and is unaffected by gender, age, body weight, ethnic origin, obesity, and mild-to-moderate hepatic impairment. Any differences in melagatran pharmacokinetics associated with these factors are attributable to differences in renal function.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This review of ximelagatran pharmacokinetics reports about 20% oral bioavailability as melagatran, peak concentrations around 2 hours after dosing, and a roughly 3-hour half-life with renal clearance, permitting fixed dosing without coagulation monitoring; it is not recommended in severe renal impairment.
Context
This review examined the pharmacokinetic and pharmacodynamic profile of the oral direct thrombin inhibitor ximelagatran compared to traditional vitamin K antagonists. Direct thrombin inhibitors are conceptually linked to the leech salivary anticoagulant hirudin. Ximelagatran is a synthetic agent, and this article contains no direct discussion of hirudotherapy, leeches, or the natural leech secretome.
Citation
Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026